The state of Virginia currently has 16 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Richmond, Charlottesville, Norfolk and Fairfax.
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021
Recruiting
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Charlottesville Medical Research, Charlottesville, Virginia
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Register for Updates
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567
Recruiting
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
All
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Carilion Children's Tanglewood Center, Roanoke, Virginia
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: McGuire Research Institute, Richmond, Virginia +1 locations
Conditions: Ulcerative Colitis
Register for Updates
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04718818
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Richmond, Virginia
Conditions: Ulcerative Colitis
Register for Updates